CVRx to Present at the William Blair 43rd Annual Growth Stock Conference
2023年5月25日 - 9:30PM
CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical
device company focused on developing, manufacturing and
commercializing innovative neuromodulation solutions for patients
with cardiovascular diseases, today announced that the management
team will present at the William Blair 43rd Annual Growth Stock
Conference on Thursday, June 8, 2023. The Company is scheduled to
present at the conference at 9:20 am Central Time (10:20 am Eastern
Time).A live audio webcast of the conference presentation will be
available online at the investor relations page of the Company’s
website at
ir.cvrx.com.
About CVRx,
Inc.CVRx is a commercial-stage medical device company
focused on developing, manufacturing and commercializing innovative
neuromodulation solutions for patients with cardiovascular
diseases. Barostim™ is the first medical technology approved by FDA
that uses neuromodulation to improve the symptoms of patients with
heart failure. Barostim is an implantable device that delivers
electrical pulses to baroreceptors located in the wall of the
carotid artery. Baroreceptors activate the body’s baroreflex, which
in turn triggers an autonomic response to the heart. The therapy is
designed to restore balance to the autonomic nervous system and
thereby reduce the symptoms of heart failure. Barostim received the
FDA Breakthrough Device designation and is FDA-approved for use in
heart failure patients in the U.S. It has also received the CE Mark
for heart failure and resistant hypertension in the European
Economic Area. To learn more about Barostim, visit
www.cvrx.com.Investor Contact:Mark Klausner or Mike VallieICR
Westwicke443-213-0501
ir@cvrx.comMedia
Contact:Laura O’NeillFinn
Partners402-499-8203
laura.oneill@finnpartners.com
CVRx (NASDAQ:CVRX)
過去 株価チャート
から 4 2024 まで 5 2024
CVRx (NASDAQ:CVRX)
過去 株価チャート
から 5 2023 まで 5 2024